MedTrace Logo

Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients

NCT01082757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1524

Last updated 2014-07-31

No results posted yet for this study

Summary

This observational, prospective, multicentric study is being conducted to record the prevalence of KRAS mutations in the Argentine mCRC population.

Conditions

  • Colorectal Neoplasms

Sponsors & Collaborators

  • Merck Quimica Argentina S.A.I.C

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Quimica Argentina S.A.I.C

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082757 on ClinicalTrials.gov